CORT · Corcept Therapeutics Inc
$114.47
+3.96 (+3.58%)
At close · Aug 14
Market Cap
$12.37B
Shares
108.10M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$207,500,000
as of 2024-01-31
· total across 2 concurrent programs
Remaining Authorization
$11,400,000
as of 2025-09-30
Program Utilization
94.5%
$196,100,000 used of $207,500,000
Concurrent Repurchase Programs
| Authorized | As of | Remaining | Remaining as of | Source |
|---|---|---|---|---|
| $200,000,000 | 2024-01-31 | — | — | 10-K, filed 2026-02-24 |
| $7,500,000 | 2023-03-31 | — | — | 10-K, filed 2026-02-24 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $0 | 10-Q, filed 2026-07-29 | ||
| 2025-12-31 | $172,915,000 | 10-K, filed 2026-02-24 | ||
| 2024-12-31 | $15,664,000 | 10-K, filed 2026-02-24 | ||
| 2023-12-31 | $0 | 10-K, filed 2026-02-24 | ||
| 2022-12-31 | $0 | 10-K, filed 2025-02-26 | ||
| 2020-12-31 | $9,945,000 | 10-K, filed 2021-02-23 | ||
| 2019-12-31 | $30,975,000 | 10-K, filed 2021-02-23 | ||
| 2018-12-31 | $23,657,000 | 10-K, filed 2021-02-23 | ||
Key facts
CIK
1088856
CUSIP
218352102
13F (30d)
390 filings
389 filers
Visit website
Investor relations